รศ.ดร.ภญ.ศริญญา คงเพชร

Publication

Scopus Author Profile

International Publication

• Hong JH, Yong CH, Heng HL, Yao X, Li Z, Sun Y, Wang P, Xiao R, Wang LC, Chen J, Guan P, Chu PL, Hagihara T, Ng SR, Jusakul A, Kongpetch S, Nargund AM, Chu WC, Ng CSY, Sugiura M, Kwek XY, Pham NA, Lin Z, Ng CCY, Lim AH, Lee JY, Chan JY, Lim KS, Liu W, Teh BS, Iqbal J, Klanrit P, Loilome W, Wai Meng Tai D, Brugarolas J, Li S, Sobota RM, Tan P, Jha S, Tan J, Teh BT. Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers. Science Translational Medicine. 2026;18(843).
• Pocasap P, Kongpetch S, Prawan A, Kaimuangpak K, Senggunprai L. Identification of Prognostic Factors in Esophageal Cancer Using Machine Learning: A Retrospective Study Based on the SEER Database. Journal of Clinical Medicine. 2026;15(8).
• Buranrat B, Sa-Ngiamwibool P, Prawan A, Kongpetch S, Pocasap P, Senggunprai L. Repurposing Rosiglitazone Induces Apoptosis Accompanied by Impaired Antioxidant Defense in Cholangiocarcinoma Cells: Findings from Proteomic and Functional Analyses. Pharmaceuticals. 2026;19(1).
• Pocasap P, Kaimuangpak K, Phukmee K, Prawan A, Kongpetch S, Senggunprai L. Unveiling the Anticancer Potential and Molecular Mechanisms of Fangchinoline Against Cholangiocarcinoma Using FTIR Microspectroscopy, In Vitro and In Silico Approaches. Integr Cancer Ther 2025; 24: 15347354251396513.
• Sa-Ngiamwibool P, Yoshinari K, Shizu R, Kongpetch S, Prawan A, Senggunprai L. Expression and Prognostic Implication of the Nuclear Receptors Farnesoid X Receptor and Pregnane X Receptor in Human Cholangiocarcinoma. Cancer Diagn Progn 2025; 5: 529-541.
• Jaidee R, Pocasap P, Jusakul A, Senggunprai L, Prawan A, Hong JH, Heng HL, Kukongviriyapan V, Teh BT, Kongpetch S. Synergistic suppression of cholangiocarcinoma cells via DNA damage response and cell cycle arrest by dual targeting PARP and ATM in DNA damage repair pathway. Biomedicine and Pharmacotherapy 2025 Jun 18; 189: 118273.
• Jaidee R, Jusakul A, Pocasap P, Kukongviriyapan V, Senggunprai L, Prawan A, Loilome W, Titapun A, Jareanrat A, Thanasukarn V, Khuntikeo N, Namwat N, Chamgramol Y, Thanee M, Wichian P, Hong JH, Guan P, Heng HL, Pairojkul C, Teh BT, Kongpetch S. Establishment and genomic profiling of cholangiocarcinoma cells with functional characterization. Sci Rep 2025 Mar 13; 15: 8621; Published online.
• Thongtoo P, Chindaprasirt J, Aphivatanasiri C, Intarawichian P, Kunprom W, Kongpetch S, Techasen A, Loilome W, Namwat N, Titapun A, Jusakul A. KRAS Mutations in Cholangiocarcinoma: Prevalence, Prognostic Value, and KRAS G12/G13 Detection in Cell-Free DNA. Cancer genomics and proteomics. 2025 Jan; 22:112-126.
• Sanlung T, Sa-Ngiamwibul P, Sookprasert A, Chindaprasirt J, Titapun A, Kongpetch S, Dornsena A, Areesinpitak T, Tassaneeyakul W, Vannaprasaht S, Wirasorn K. Excision Repair Cross-Complementation Group 1 (ERCC1) Polymorphism Predicted Platinum-Based Chemotherapy Treatment Outcome in Cholangiocarcinoma. Journal of the Medical Association of Thailand. 2024 Nov;107(1):S63-70.
• Pocasap P, Prawan A, Kongpetch S, Senggunprai L. Network pharmacology- and cell-based assessments identify the FAK/Src pathway as a molecular target for the antimetastatic effect of momordin Ic against cholangiocarcinoma. Heliyon. 2024 June; 10: e32352.
• Mahaamnad N, Pocasap P, Kukongviriyapan V, Senggunprai L, Prawan A, Kongpetch S. Dual blockage of PI3K-mTOR and FGFR induced autophagic cell death in cholangiocarcinoma cells. Heliyon. 2024 May; 10: e31112.
• Janthamala S, Promraksa B, Thanee M, Duenngai K, Jusakul A, Kongpetch S, Kraiklang R, Thanee K, Pinlaor P, Namwat N, Saya H, Techasen A. Anticancer properties and metabolomic profiling of Shorea roxburghii extracts toward gastrointestinal cancer cell lines. BMC Complement Med Ther. 2024 Apr 30;24(1):178.
• Khosla D, Misra S, Chu PL, Guan P, Nada R, Gupta R, Kaewnarin K, Ko TK, Heng HL, Srinivasalu VK, Kapoor R, Singh D, Klanrit P, Sampattavanich S, Tan J, Kongpetch S, Jusakul A, Teh BT, Chan JY, Hong JH. Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches. Cancers (Basel) 2024; 16.
• Hong JH, Yong CH, Heng HL, Chan JY, Lau MC, Chen J, Lee JY, Lim AH, Li Z, Guan P, Chu PL, Boot A, Ng SR, Yao X, Wee FYT, Lim JCT, Liu W, Wang P, Xiao R, Zeng X, Sun Y, Koh J, Kwek XY, Ng CCY, Klanrit P, Zhang Y, Lai J, Tai DWM, Pairojkul C, Dima S, Popescu I, Hsieh SY, Yu MC, Yeong J, Kongpetch S, Jusakul A, Loilome W, Tan P, Tan J, Teh BT. Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies. Gut. 2023 Nov 24:gutjnl-2023-330483. doi: 10.1136/gutjnl-2023-330483. Online ahead of print.
• Oeurn K, Jusakul A, Jaidee R, Kukongviriyapan V, Senggunprai L, Prawan A, Kongpetch S. FGF10/FGFR2 Signaling: Therapeutically Targetable Vulnerability in Ligand-responsive Cholangiocarcinoma Cells. In Vivo. 2023 Jul-Aug;37(4):1628-1637.
• Sirithawat P, Jusakul A, Kongpetch S, Thanee M, Srichanchara P, Panjaroensak S, Kimawaha P, Janthamala S, Aphivatanasiri C, Techasen A. Alteration of STK11 Expression Associated With Cholangiocarcinoma Progression. In Vivo. 2023 Jul-Aug;37(4):1638-1648. doi: 10.21873/invivo.13249.
• Malikrong P, Prawan A,Kongpetch S, Senggunprai L. Momordin ic triggers mitochondria-mediated apoptosis of cholangiocarcinoma cells and enhances the efficacy of conventional chemotherapeutic drugs. Farmacia. 2023 Feb;71(3):518–525.
• Butsri S, Kukongviriyapan V, Senggunprai L, Kongpetch S, Prawan A. 13-cis-retinoic acid inhibits the self-renewal, migration, invasion and adhesion of cholangiocarcinoma cells. Int J Mol Med 2023; 51. Published online 2023 Jan 21.
• Kaewmeesri P, Pocasap P, Kukongviriyapan V, Prawan A, Kongpetch S, Senggunprai L. Anti-metastatic Potential of Natural Triterpenoid Cucurbitacin B Against Cholangiocarcinoma Cells by Targeting Src Protein. Integr Cancer Ther 2022 Sep 27; 21: 15347354221124861.
• Senggunprai L, Kukongviriyapan V, Prawan A, Kongpetch S. Epidermal growth factor receptor as a potential target of momordin Ic to promote apoptosis of cholangiocarcinoma cells. J Pharm Pharmacol . 2022 Jul 15;74(7):996-1005.
• Butsri S, Kukongviriyapan V, Senggunprai L, Kongpetch S, Prawan A. All-trans-retinoic acid induces RARB-dependent apoptosis via ROS induction and enhances cisplatin sensitivity by NRF2 downregulation in cholangiocarcinoma cells. Oncol Lett. 2022 Jun;23(6):179.
• Jaidee R, Kukongviriyapan V, Senggunprai L, Prawan A, Jusakul A, Laphanuwat P, Kongpetch S. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways. Life Sci. 2022 May 1; 296: 120427.
• Tessiri S, Techasen A, Kongpetch S, Namjan A, Loilome W, Chan-On W, Thanan R, Jusakul A. Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma. PeerJ. 2022 Jan 13; 10: e12750.
• Laphanuwat P, Kongpetch S, Senggunprai L, Prawan A, Kukongviriyapan V. Licochalcone A Induces Cholangiocarcinoma Cell Death Via Suppression of Nrf2 and NF-kappaB Signaling Pathways. Asian Pac J Cancer Prev. 2022 Jan 1; 23: 115-123.

National Publication

• Boonloh K, Pocasap P. Kongpetch S, Pannangpetch P, Kukongviriyapan V. Unveiling the Mechanism of Madecassic Acid in Nonalcoholic Fatty Liver Disease: A Network Pharmacology and Experimental Validation. J. Basic. App. Pharmacol. 2024 Jul-Dec;4(2):108-120.